Neurosense Therapeutics is trading at $0.53, up 5.68%, after its August 6 announcement targeting a December 2026 Health Canada filing for PrimeC.
- The company completed the pre-NDS process and reported regulatory alignment, supporting continued investor interest.
- Shares previously touched $0.56, up 7.5% from the prior close.
- Broader markets remain mixed; live-trading volume and activity-level data were unavailable.